Outlook Therapeutics (OTLK) EPS (Weighted Average and Diluted): 2016-2024
Historic EPS (Weighted Average and Diluted) for Outlook Therapeutics (OTLK) over the last 8 years, with Sep 2024 value amounting to -$4.06.
- Outlook Therapeutics' EPS (Weighted Average and Diluted) was N/A to $0.02 in Q3 2020 from the same period last year, while for Sep 2020 it was -$0.25, marking a year-over-year change of. This contributed to the annual value of -$4.06 for FY2024, which is 13.98% up from last year.
- According to the latest figures from FY2024, Outlook Therapeutics' EPS (Weighted Average and Diluted) is -$4.06, which was up 13.98% from -$4.72 recorded in FY2023.
- Outlook Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.31 during FY2022, with a 5-year trough of -$4.72 in FY2023.
- For the 3-year period, Outlook Therapeutics' EPS (Weighted Average and Diluted) averaged around -$3.03, with its median value being -$4.06 (2024).
- In the last 5 years, Outlook Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 47.76% in 2021 and then slumped by 1,422.58% in 2023.
- Yearly analysis of 5 years shows Outlook Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.67 in 2020, then spiked by 47.76% to -$0.35 in 2021, then climbed by 11.43% to -$0.31 in 2022, then plummeted by 1,422.58% to -$4.72 in 2023, then grew by 13.98% to -$4.06 in 2024.